Objectives: In the last three decades, Glutathione STransferase P1 (GSTP1) 105IIe>Val had been extensively reported in the case of Bladder cancer (BC). However, conflicting results were observed among the studies. We aimed to perform a meta-analysis in effort to assess the association between GSTP1 105IIe>Val gene polymorphism and the risk of BC. Material and Methods: A meta-analysis was conducted between May and July 2019. Papers were searched in Pubmed, Embase, Cochrane, and Web of Science and information of interest was extracted. The correlation and effect estimation were analyzed using random or fixed effect model. Results: We collected 17 studies consisting of 4.236 cases and 5.085 controls. Our pooled calculation revealed that GSTP1 105IIe>Val gene polymorphism was not associated with the risk of BC (OR 95%CI=1.11 [0.97-1.26], p=0.1190). We also performed sub-group analyses in accordance with ethnicity and genotyping method. In ethnicity sub-group, we failed to clarify the correlation between GSTP1 105IIe>Val gene polymorphism and the risk of BC both in Asian and Caucasian sub-groups. While, in genotyping method sub-groups, either using polymerase chain reaction (PCR) or PCR-Restriction fragment length polymorphism (PCR-RFLP) had no significant association with the risk of BC. Conclusion: There is no association between GSTP1 105IIe>Val gene polymorphism and the risk of BC.
Keywords: Bladder cancer; GSTP1; SNP; meta-analysis
Amaç: Son 30 yılda, Glutatyon S-Transferaz P1 (GSTP1) 105IIe>Val mesane kanseri (MK) vakalarında yoğun olarak bildirildi. Fakat çalışmalar arasında çelişkili sonuçlar vardı. GSTP1 105IIe>Val gen polimorfizmi ve MK riski arasındaki ilişkiyi değerlendirmek için bir metaanaliz yapmayı amaçladık. Gereç ve Yöntemler: Mayıs ve Temmuz 2019 arasında meta-analiz yapıldı. Pubmed, Embase, Cochrane ve Web of Science'daki makaleler araştırıldı ve ilgili bilgiler alındı. Korelasyon ve etki tahmini rastgele veya sabit etki modeli kullanılarak incelendi. Bulgular: Toplam 4.236 olgu ve 5.085 kontrolü kapsayan 17 çalışmayı topladık. Toplanmış hesaplama GSTP1 105IIe>Val gen polimorfizminin MK riski ile ilişkili olmadığını ortaya koydu (OR %95 GA=1.11[0,97-1,26], p=0,1190). Ayrıca etnisite ve genotiplendirme yöntemine uygun olarak alt grup analizleri yaptık. Etnisite alt grubunda, hem Asyalı hem de vrupalı ırkta GSTP1 105IIe>Val gen polimorfizmi ile BK arasındaki korelasyonu açıklayamadık. Genotiplendirme yöntemi alt gruplarında, polimeraz zincir reaksiyonu (PCR) veya PCR-kısıtlama fragman uzunluğu polimorfizmi (PCR-RFLP) kullanarak MK ile ilişki bulmadık. Sonuç: GSTP1 105IIe>Val gen polimorfizmi ile MK riski arasında ilişki yoktur.
Anahtar Kelimeler: Mesane kanseri; GSTP1; SNP; meta-analiz
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359-86. [Crossref] [PubMed]
- Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-41. [Crossref] [PubMed]
- Kauppinen T, Toikkanen J, Pedersen D, Young R, Ahrens W, Boffetta P, et al. Occupational exposure to carcinogens in the European Union. Occup Environ Med. 2000;57(1):10-8. [Crossref] [PubMed] [PMC]
- Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D. Gene polymorphisms in bladder cancer. Urol Oncol. 2008;26(1):1-8. [Crossref] [PubMed]
- Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 1997;18(4):641-4. [Crossref] [PubMed]
- Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;6(7):e1000097. [Crossref] [PubMed] [PMC]
- Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009;169(4):505-14. [Crossref] [PubMed] [PMC]
- Bae JM. Comparison of methods of extracting information for meta-analysis of observational studies in nutritional epidemiology. Epidemiol Health. 2016;38:e2016003. [Crossref] [PubMed] [PMC]
- Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y. CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol. 2009;41(2):259-66. [Crossref] [PubMed]
- Altunkol A, Savas M, Dilmec F, Utangac M, Abat D, Gumus K, et al. Detection of CYP1A1 and GSTP1 gene polymorphisms in bladder cancer patients in a Turkish population using a polymerase chain reaction-restriction fragment length polymorphism method. Turkish Journal of Urology. 2018;44(2):125-31. [Crossref] [PubMed] [PMC]
- Broberg K, Björk J, Paulsson K, Höglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26(7):1263-71. [Crossref] [PubMed]
- Fontana L, Delort L, Joumard L, Rabiau N, Bosviel R, Satih S, et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res. 2009;29(5):1631-5.
- García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649-59. [Crossref]
- Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004;110(4):598-604. [Crossref] [PubMed]
- Kopps S, Angeli-Greaves M, Blaszkewicz M, Prager HH, Roemer HC, Löhlein D, et al. Glutathione S-transferase P1 ILE105Val polymorphism in occupationally exposed bladder cancer cases. J Toxicol Environ Health A. 2008;71(13-14):898-901. [Crossref] [PubMed]
- Lesseur C, Gilbert-Diamond D, Andrew AS, Ekstrom RM, Li Z, Kelsey K, et al. A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire. Toxicol Lett. 2012;210(1):100-6. [Crossref] [PubMed] [PMC]
- Ma QW, Lin GF, Chen JG, Shen JH. Polymorphism of glutathione S-transferase T1, M1 and P1 genes in a Shanghai population: patients with occupational or non-occupational bladder cancer. Biomed Environ Sci. 2002;15(3):253-60.
- Yuan JM, Chan KK, Coetzee GA, Castelao JE, Watson MA, Bell DA, et al. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis. 2008;29(7):1386-93. [Crossref] [PubMed] [PMC]
- Pandith A, Lateef A, Shahnawaz S, Hussain A, Malla T, Azad N, et al. GSTP1 gene Ile105Val polymorphism causes an elevated risk for bladder carcinogenesis in smokers. Asian Pac J Cancer Prev. 2013;14(11):6375-8. [Crossref] [PubMed]
- Reszka E, Jablonowski Z, Wieczorek E, Jablonska E, Krol M, Gromadzinska J, et al. Polymorphisms of NRF2 and NRF2 target genes in urinary bladder cancer patients. J Cancer Res Clin Oncol. 2014;140(10):1723-31. [Crossref] [PubMed] [PMC]
- Steinhoff C, Franke KH, Golka K, Thier R, Römer HC, Rötzel C, et al. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol. 2000;74(9):521-6. [Crossref] [PubMed]
- Hsu LI, Chiu AW, Huan SK, Chen CL, Wang YH, Hsieh FI, et al. SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol. 2008;228(2):144-55. [Crossref] [PubMed]
- Mittal RD, Shankar D, Srivastava L, Mandhani A, Mittal B. Genetic polymorphism of drug metabolizing enzymes (CYP2E1, GSTP1) and susceptibility to bladder cancer in North India. Asian Pac J Cancer Prev. 2005;6(1):6-9.
- Törüner GA, Akyerli C, Uçar A, Aki T, Atsu N, Ozen H, et al. Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol. 2001;75(8):459-64. [Crossref] [PubMed]
- Kellen E, Hemelt M, Broberg K, Golka K, Kristensen VN, Hung RJ, et al. Pooled analysis and meta-analysis of the glutathione S-transferase P1 Ile 105Val polymorphism and bladder cancer: a HuGE-GSEC review. Am J Epidemiol. 2007;165(11):1221-30. [Crossref] [PubMed]
- Wu K, Wang X, Xie Z, Liu Z, Lu Y. Glutathione S-transferase P1 gene polymorphism and bladder cancer susceptibility: an updated analysis. Mol Biol Rep. 2012;40(1):687-95. [Crossref] [PubMed]
- Wang Z, Xue L, Chong T, Li H, Chen H, Wang Z. Quantitative assessment of the association between glutathione S-transferase P1 Ile105Val polymorphism and bladder cancer risk. Tumor Biol. 2013;34(3):1651-7. [Crossref] [PubMed]
- Yu Y, Li X, Liang C, Tang J, Qin Z, Wang C, et al. The relationship between GSTA1, GSTM1, GSTP1, and GSTT1 genetic polymorphisms and bladder cancer susceptibility. Medicine (Baltimore). 2016;95(37):e4900. [Crossref] [PubMed] [PMC]
- Namipashaki A, Razaghi-Moghadam Z, Ansari-Pour N. The essentiality of reporting Hardy-Weinberg equilibrium calculations in population-based genetic association studies. Cell J. 2015;17(2):187-92.
- Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis. 2018;7(1):8. [Crossref] [PubMed] [PMC]
- Simić T, Savić-Radojević A, Plje?a-Ercegovac M, Matić M, Sa?ić T, Dragičević D, et al. The role of glutathione s-transferases in urinary tract tumors. J Med Biochem. 2008;27(3):360-6. [Crossref]
- Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249(22):7130-9.
- Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45(1):51-88. [Crossref] [PubMed]
- Pljesa-Ercegovac M, Savic-Radojevic A, Kravic-Stevovic T, Bumbasirevic V, Mimic-Oka J, Simic T. Co-localization of GSTP1 and JNK in transitional cell carcinoma of urinary bladder. Genet Mol Biol. 2010;33(3):460-2. [Crossref] [PubMed] [PMC]
- Adler V, Pincus MR. Effector peptides from glutathione-S-transferase-pi affect the activation of Jun by Jun-N-terminal kinase. Ann Clin Lab Sci. 2004;34(1):35-46.
- Ketterer B. A bird's eye view of the glutathione transferase field. Chem Biol Interact. 2001;138(1):27-42. [Crossref]
- Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MAT, et al. Glutathione S-transferase P1: gene sequence variation and functional genomic studies. Cancer Res. 2008;68(12):4791-801. [Crossref] [PubMed] [PMC]
- Sharma A, Pandey A, Sharma S, Chatterjee I, Mehrotra R, Sehgal A, et al. Genetic polymorphism of glutathione S-transferase P1 (GSTP1) in Delhi population and comparison with other global populations. Meta Gene. 2014;2:134-42. [Crossref] [PubMed] [PMC]
- Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10(12):1239-48.
- Uhlen M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419. [Crossref] [PubMed]
.: İşlem Listesi